Page last updated: 2024-11-04

pyridinolcarbamate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pyridinolcarbamate: A drug that has been given by mouth in the treatment of atherosclerosis and other vascular disorders, hyperlipidemias, and thrombo-embolic disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1408) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4990
CHEMBL ID1620144
CHEBI ID32075
SCHEMBL ID253857
MeSH IDM0018235

Synonyms (89)

Synonym
pyricarbato
unii-81r511uv73
5-21-04-00441 (beilstein handbook reference)
81r511uv73 ,
pyricarbatum
piridinol carbamato
2,6-pyridinediyldimethylene bis(methylcarbamate)
2,6-pyridinedimethanol, bis(methylcarbamate) (ester)
colesterinex
piridinol carbamato [spanish]
duvaline
brn 1544252
vasoverin
h-3749
pyricarbate [inn]
pyricarbato [inn-spanish]
vasapril
aterosan
pyridinolcarbamate
carbamic acid, methyl-, 2,6-pyridinediyldimethylene ester
cicloven
movecil
vasagin
sospitan
einecs 217-538-9
pyricarbatum [inn-latin]
veranterol
vasocil
methylcarbamic acid 2,6-pyridinediyldimethylene ester
atover
smr000045425
MLS000040427 ,
ravenil
pyridinol carbamate
pyricarbate
1882-26-4
OPREA1_494883
parmidine
anginine
prodectin
[6-(methylcarbamoyloxymethyl)-2-pyridyl]methyl n-methylcarbamate
anginin
angioxine
2,6-pyridinedimethanol bis(methylcarbamate) ester
sospitan 500
parmidine r
pyridinol carbamate (jan)
D01396
angioxine (tn)
anginin (tn)
NCGC00074022-02
pyridine-2,6-diyldimethanediyl bis(methylcarbamate)
STL048564
HMS1612N04
[6-(methylcarbamoyloxymethyl)pyridin-2-yl]methyl n-methylcarbamate
AKOS001642843
CHEMBL1620144
chebi:32075 ,
tox21_110989
cas-1882-26-4
dtxsid5045708 ,
dtxcid3025708
CCG-110891
FT-0684249
pyridine-2,6-diyldi(methylene)-bis(methylcarbamate)
pyridinol carbamate [jan]
2,6-pyridinylenebis(methyl-n-methylcarbamate)
pyricarbate [inci]
pyricarbate [mart.]
pyridinol carbamate [mi]
2,6-pyridinedimethanol bis(methylcarbamate) (ester)
pyricarbate [who-dd]
SCHEMBL253857
pyridine-2,6-diyldi(methylene) bis(methylcarbamate)
YEKQSSHBERGOJK-UHFFFAOYSA-N
prodectine
2,6-pyridinedimethanol, bis(methylcarbamate)
parmidin
n-methylcarbamic acid [6-(methylcarbamoyloxymethyl)-2-pyridinyl]methyl ester;hydrochloride
n-methylcarbamic acid [6-(methylcarbamoyloxymethyl)-2-pyridyl]methyl ester;hydrochloride
bdbm55239
[6-(methylcarbamoyloxymethyl)pyridin-2-yl]methyl n-methylcarbamate;hydrochloride
cid_6602723
[6-({[(methylamino)carbonyl]oxy}methyl)-2-pyridinyl]methyl methylcarbamate
mfcd00473700
pyridine-2,6-diylbis(methylene) bis(methylcarbamate)
Q27114774
(6-{[(methylcarbamoyl)oxy]methyl}pyridin-2-yl)methyl n-methylcarbamate
LS-04729

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"58 micrograms) but the half-life was unchanged (6."( Pharmacokinetic study of pyridinol carbamate in chronic renal insufficiency.
François, B; Ksavrelof, H; Mallein, R; Rondelet, J,
)
0.13

Compound-Compound Interactions

ExcerptReferenceRelevance
"Two antiplatelet drugs, pyridinolcarbamate and Sudoxicam, were tested separately and in combination with heparin for their ability to modify experimental hyperacute renal allograft rejection in primates."( Hyperacute renal allograft rejection in the primate. Therapeutic limitations of antiplatelet agents alone and combined with heparin.
Birtch, AG; Busch, GJ; Colman, RW; Habal, M; Hollenberg, NK, 1976
)
0.56

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"The use of lathyric toxins (BAPN) in low dosage (1 g/kg/day) for a period of 8 weeks caused in the rat simultaneous changes in the skin and aortic connective tissues."( [Chronic lathyrism. Protective effect of pyridinol carbamate on connective tissue lesions in the rat (author's transl)].
Bouissou, H; Foulquier, F; Julian, M; Pieraggi, MT; Vila, C, 1977
)
0.26
" As the dosage of N-nitroso pyridinol carbamate increased, the number of revertant colonies also increased."( Mutagenicity of N-nitroso pyridinol carbamate with the Salmonella/mammalian microsome test.
Börzönyi, B; Ferencz, A; Kiss, K; Nádasdi, I; Pintér, A; Roller, PP; Surján, A; Török, G, 1979
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (219)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990176 (80.37)18.7374
1990's11 (5.02)18.2507
2000's2 (0.91)29.6817
2010's6 (2.74)24.3611
2020's24 (10.96)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.77 (24.57)
Research Supply Index5.63 (2.92)
Research Growth Index5.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials20 (7.72%)5.53%
Reviews10 (3.86%)6.00%
Case Studies12 (4.63%)4.05%
Observational0 (0.00%)0.25%
Other217 (83.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]